
The Cognition Institute’s series of public talks and debates is starting up again for 2013.
Please join us for January’s CogTalk -details below:
Smart drugs for smarter people: Cognitive Enhancement and becoming superhuman.
18:00 Thurs 24th January 2013 Peninsula Arts Gallery Wake up and smell the coffee! Most people are comfortable drinking an espresso to boost alertness, but would they feel as happy about using drugs that treat sleeping problems or ADHD, which have the same effect? Or what about taking a drug that improves your memory, just before an exam?
In this month’s CogTalk, Professor Ruud ter Meulen and Dr Stephen Hall will consider the ethics of using ‘smart drugs’. They’ll discuss whether some forms of cognitive enhancement are more acceptable than others? What parallels are there with doping in sports? Should we be encouraged to boost our working hours by taking drugs?
Ruud ter Meulen is Professor of Ethics in Medicine at the Universty of Bristol, who specialises in the field of bio-ethics. Stephen Hall is Director of the Aston Brain Stimulation Laboratory and a neuropharmacologist, with expertise in cognitive enhancement research.
Entrance Free. All welcome.
Seating is limited so booking is essential Box Office: 01752 58 50 50 / peninsula-arts@plymouth.ac.uk
http://www1.plymouth.ac.uk/research/cognition/Pages/default.aspx











3C Online Social: Thursday 26 March 1–2pm – Research Culture, Community & Can you Guess Who?
Four BU students at national midwifery conference
INRC book roundtable/presentation by Drs Jonathan Cole and Catherine Talbot, Wednesday 22/04/2026, 13:00h, P426
BU M.Res. student’s evidence to UK Parliamentary Women & Equalities Committee
Prof Marahatta promoting BU-Nepal collaboration
ECR Funding Open Call: Research Culture & Community Grant – Apply now
ECR Funding Open Call: Research Culture & Community Grant – Application Deadline Friday 12 December
MSCA Postdoctoral Fellowships 2025 Call
ERC Advanced Grant 2025 Webinar
Update on UKRO services
European research project exploring use of ‘virtual twins’ to better manage metabolic associated fatty liver disease